AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23002720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 20503056 — intervention group
Group type: EXPERIMENTAL
Intervention: VH(0.21)
Number of subjects: 8
Study 20503056 — intervention group
Group type: EXPERIMENTAL
Intervention: NB(0.157)
Number of subjects: 8
Study 20503056 — intervention group
Group type: COMPARATOR
Intervention: VH(0.29)
Number of subjects: 8
Study 20503056 — intervention group
Group type: COMPARATOR
Intervention: NB(0.21)
Number of subjects: 8
Study 17987126 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-derived lignan capsules (360 mg lignan per day)
Number of subjects: 73
Study 17987126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 17987126 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-derived lignan capsules
Number of subjects: 73
Study 15220366 — intervention group
Group type: COMPARATOR
Intervention: Usual care patients on various statins (n=97)
Number of subjects: 1584
Study 15220366 — intervention group
Group type: COMPARATOR
Intervention: Structured care patients on atorvastatin (n=783)
Number of subjects: 1584
Study 15220366 — intervention group
Group type: COMPARATOR
Intervention: Untreated dyslipidaemic patients (n=704)
Number of subjects: 1584
Study 12365090 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (T) 40 mg once daily
Number of subjects: 441
Study 12365090 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (P) 4 mg once daily
Number of subjects: 441
Study 9650623 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward contingencies
Number of subjects: 63
Study 9650623 — intervention group
Group type: EXPERIMENTAL
Intervention: Response cost contingencies
Number of subjects: 63
Study 9650623 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 63
Study 7866482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA, tacrine) treatment for 1 year
Number of subjects: 0
Study 2527537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazaprilat (2 mg intravenous infusion)
Number of subjects: 0
Study 2527537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 193178 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization after acute myocardial infarction
Number of subjects: 0
Study 193178 — intervention group
Group type: COMPARATOR
Intervention: Prolonged bed rest
Number of subjects: 0
Study 29869014 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive chevron osteotomy (MIS group)
Number of subjects: 47
Study 29869014 — intervention group
Group type: COMPARATOR
Intervention: Open chevron technique (OC group)
Number of subjects: 47
Study 28363222 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 12944
Study 28363222 — intervention group
Group type: COMPARATOR
Intervention: BARC type 2 bleeding
Number of subjects: 12944
Study 28363222 — intervention group
Group type: COMPARATOR
Intervention: BARC type 3a bleeding
Number of subjects: 12944
Study 28363222 — intervention group
Group type: COMPARATOR
Intervention: BARC type 3b bleeding
Number of subjects: 12944
Study 28363222 — intervention group
Group type: COMPARATOR
Intervention: BARC type 3c bleeding
Number of subjects: 12944
Study 26787687 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg twice daily for 14 days
Number of subjects: 30
Study 26787687 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 500 mg twice daily for 14 days
Number of subjects: 30
Study 26787687 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 1000 mg twice daily for 14 days
Number of subjects: 30
Study 26787687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25176098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.5 mg bevacizumab
Number of subjects: 33
Study 25176098 — intervention group
Group type: COMPARATOR
Intervention: Non-intravitreal treatment (only vitreous operation and membrane peeling)
Number of subjects: 33
Study 22135385 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 11040
Study 22135385 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/d atorvastatin
Number of subjects: 11040
Study 22135385 — intervention group
Group type: COMPARATOR
Intervention: 20-40 mg/d simvastatin
Number of subjects: 11040
Study 20560292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200-2000 mg/day)
Number of subjects: 27
Study 20560292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17242096 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP‐40 group (n = 20)
Number of subjects: 60
Study 17242096 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP‐20 group (n = 20)
Number of subjects: 60
Study 17242096 — intervention group
Group type: COMPARATOR
Intervention: PEEP‐5 group (n = 20)
Number of subjects: 60
Study 16037723 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma management education program (group education once, reinforcement education three times)
Number of subjects: 61
Study 16037723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no asthma management education)
Number of subjects: 61
Study 12111030 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced key-worker liaison
Number of subjects: 84
Study 12111030 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 84
Study 10447227 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (400 mg capsules twice a day for 2 years)
Number of subjects: 100
Study 10447227 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional therapy)
Number of subjects: 100
Study 10447227 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 100
Study 10447227 — intervention group
Group type: COMPARATOR
Intervention: Clodronate and Control
Number of subjects: 100
Study 7499633 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire administered before physician or family nurse practitioner visit
Number of subjects: 200
Study 2264006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 250 mg IM
Number of subjects: 175
Study 2264006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 500 mg IM
Number of subjects: 175
Study 7358205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 58
Study 7358205 — intervention group
Group type: COMPARATOR
Intervention: Xanthinol nicotinate
Number of subjects: 58
Study 31615197 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping training with external feedback for lower limb support ability
Number of subjects: 36
Study 31615197 — intervention group
Group type: COMPARATOR
Intervention: Stepping training without external feedback (control)
Number of subjects: 36
Study 30764648 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus medication (escitalopram)
Number of subjects: 112
Study 30764648 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus CBT (CBT added after antidepressant)
Number of subjects: 112
Study 30764648 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (CBT plus medication or medication plus CBT)
Number of subjects: 112
Study 30764648 — intervention group
Group type: COMPARATOR
Intervention: CBT plus medication and Medication plus CBT
Number of subjects: 112
Study 28353407 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 927
Study 28353407 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 927
Study 28353407 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol
Number of subjects: 927
Study 25993594 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/day) plus standard ADHF therapy
Number of subjects: 100
Study 25993594 — intervention group
Group type: COMPARATOR
Intervention: Standard ADHF therapy alone (Control)
Number of subjects: 100
Study 24315312 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 124
Study 24315312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22146614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 μg kg(‐1)
Number of subjects: 17
Study 22146614 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 17
Study 21123574 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN115
Number of subjects: 21
Study 17985810 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg citrus flavonoids plus 30 mg tocotrienols (S)
Number of subjects: 140
Study 17985810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 140
Study 15848148 — intervention group
Group type: EXPERIMENTAL
Intervention: UWSFR measured at 11:30 a.m.
Number of subjects: 108
Study 15848148 — intervention group
Group type: EXPERIMENTAL
Intervention: UWSFR in the very low group at 11:30 a.m.
Number of subjects: 108
Study 15848148 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of oral dryness ratings using Visual Analog Scales.
Number of subjects: 108
Study 15848148 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of oral wetness in low and very low UWSFR groups at 11:30 a.m.
Number of subjects: 108
Study 12050336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 238
Study 12050336 — intervention group
Group type: COMPARATOR
Intervention: Standard stent
Number of subjects: 238
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 5 mg
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 2.5 mg
Number of subjects: 243
Study 9869018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg (24 h ambulatory)
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 2.5 mg (24 h ambulatory)
Number of subjects: 243
Study 9869018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 h ambulatory)
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 5 mg (24 h ambulatory)
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothness index for 2.5 mg lercanidipine
Number of subjects: 243
Study 9869018 — intervention group
Group type: COMPARATOR
Intervention: Smoothness index for placebo
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothness index for 5 mg lercanidipine
Number of subjects: 243
Study 9869018 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothness index for 10 mg lercanidipine
Number of subjects: 243
Study 7890052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceed
Number of subjects: 66
Study 7890052 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery alone (Control)
Number of subjects: 66
Study 2223155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin treatment in invasive treatment group
Number of subjects: 54
Study 2223155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin treatment in non-invasive treatment group
Number of subjects: 54
Study 2223155 — intervention group
Group type: COMPARATOR
Intervention: Control group in invasive treatment
Number of subjects: 54
Study 2223155 — intervention group
Group type: COMPARATOR
Intervention: Control group in non-invasive treatment
Number of subjects: 54
Study 6932055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 6932055 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone
Number of subjects: 0
Study 6932055 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study 31919773 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus micropulse laser (group A)
Number of subjects: 40
Study 31919773 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept monotherapy (group B)
Number of subjects: 40
Study 30489140 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Forward with peer support
Number of subjects: 30
Study 30489140 — intervention group
Group type: COMPARATOR
Intervention: Thinking Forward without peer support
Number of subjects: 30
Study 28957699 — intervention group
Group type: EXPERIMENTAL
Intervention: AraC with MK-8776 (Arm A)
Number of subjects: 32
Study 28957699 — intervention group
Group type: COMPARATOR
Intervention: AraC alone (Arm B)
Number of subjects: 32
Study 28957699 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8776
Number of subjects: 32
Study 28957699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 26348542 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal (125 mg)
Number of subjects: 12
Study 26348542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23464844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-resistant Gram-negative coliforms identified in rectal flora
Number of subjects: 865
Study 23464844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin use in the past 3 months
Number of subjects: 865
Study 23464844 — intervention group
Group type: EXPERIMENTAL
Intervention: History of heart valve replacement
Number of subjects: 865
Study 23464844 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious complications post-biopsy
Number of subjects: 865
Study 23464844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin resistance and infectious complications
Number of subjects: 865
Study 21183734 — intervention group
Group type: EXPERIMENTAL
Intervention: INV-403 (20 mg/kg per day)
Number of subjects: 0
Study 19028085 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Asthma Quality of Life Questionnaire (AQLQ(S))
Number of subjects: 116
Study 19028085 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Asthma Control Questionnaire (ACQ)
Number of subjects: 116
Study 19028085 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S))
Number of subjects: 116
Study 19028085 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Asthma Quality of Life Questionnaire (AQLQ(S))
Number of subjects: 116
Study 19028085 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Asthma Control Questionnaire (ACQ)
Number of subjects: 116
Study 19028085 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S))
Number of subjects: 116
Study 17188581 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 330
Study 17188581 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CCAB)
Number of subjects: 330
Study 16870812 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infections (SI)
Number of subjects: 60
Study 16870812 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC viral stimulation with cognate myelin Ag
Number of subjects: 60
Study 16870812 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples during exacerbations associated with SI
Number of subjects: 60
Study 12597703 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg MPH
Number of subjects: 23
Study 12597703 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MPH
Number of subjects: 23
Study 12597703 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg MPH
Number of subjects: 23
Study 12597703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11020741 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐122,721 200 mg
Number of subjects: 243
Study 11020741 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐122,721 100 mg
Number of subjects: 243
Study 11020741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CP‐122,721 200 mg + ondansetron 4 mg)
Number of subjects: 243
Study 11020741 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 243
Study 9148198 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly salient (pop out) distractors
Number of subjects: 0
Study 9148198 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimanual response with right hand
Number of subjects: 0
Study 9148198 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractors presented in the same visual halffield as targets
Number of subjects: 0
Study 1739372 — intervention group
Group type: EXPERIMENTAL
Intervention: MDC (multiple-dose charcoal)
Number of subjects: 9
Study 1739372 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI (whole-bowel irrigation)
Number of subjects: 9
Study 1739372 — intervention group
Group type: COMPARATOR
Intervention: CTL (control)
Number of subjects: 9
Study 6386031 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial X-ray therapy (100 rad at 50 kV on three occasions at intervals of 21 days)
Number of subjects: 24
Study 6386031 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control hand)
Number of subjects: 24
Study 31779726 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-service socio-economic factors (absence of debt, stable housing, relationship satisfaction)
Number of subjects: 13856
Study 31779726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health and alcohol problems (probable PTSD, symptoms of common mental disorder, aggressive behaviour)
Number of subjects: 13856
Study 31779726 — intervention group
Group type: COMPARATOR
Intervention: Leaving military service
Number of subjects: 13856
Study 30583233 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (tVNS)
Number of subjects: 94
Study 30583233 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the earlobe
Number of subjects: 94
Study 28158152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling therapy
Number of subjects: 64
Study 28158152 — intervention group
Group type: COMPARATOR
Intervention: Cross tape therapy
Number of subjects: 64
Study 25187003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS) - 10 twice weekly meetings focused on a specific cognitive area.
Number of subjects: 0
Study 25187003 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (CT)
Number of subjects: 0
Study 25187003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation (CS)
Number of subjects: 0
Study 24083759 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant EGF-based cream
Number of subjects: 40
Study 24083759 — intervention group
Group type: COMPARATOR
Intervention: General supportive skin care (Control)
Number of subjects: 40
Study 18304284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 403
Study 18304284 — intervention group
Group type: COMPARATOR
Intervention: Transdermal E2/NETA (50 microg/140 microg)
Number of subjects: 403
Study 18304284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 403
Study 16444068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone agonists (GnRH agonists)
Number of subjects: 0
Study 16444068 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated slowly progressive variants of central precocious puberty)
Number of subjects: 0
Study 15041351 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA microemulsification formulation (CsA‐ME)
Number of subjects: 0
Study 15041351 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME using C2 monitoring
Number of subjects: 0
Study 15041351 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 0
Study 15041351 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME
Number of subjects: 0
Study 11422967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral notches/mean resistance index >= 0.65
Number of subjects: 689
Study 11422967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral notches/mean resistance index >= 0.55 and unilateral notches/mean resistance index >= 0.65 combined with inhibin-A >= 1.0 multiples of the median
Number of subjects: 689
Study 11422967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral notches
Number of subjects: 689
Study 11422967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method of uterine artery notch data with inhibin-A
Number of subjects: 689
Study 9258877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum plasma thrombomodulin levels in preeclamptic women
Number of subjects: 58
Study 9258877 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum plasma thrombomodulin levels in preeclamptic women
Number of subjects: 58
Study 9258877 — intervention group
Group type: COMPARATOR
Intervention: Antepartum plasma thrombomodulin levels in normotensive controls
Number of subjects: 58
Study 9258877 — intervention group
Group type: COMPARATOR
Intervention: Postpartum plasma thrombomodulin levels in normotensive controls
Number of subjects: 58
Study 8507027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF rinse used once daily
Number of subjects: 95
Study 8507027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel applied twice daily
Number of subjects: 95
Study 8507027 — intervention group
Group type: COMPARATOR
Intervention: 1100 ppm fluoride toothpaste alone
Number of subjects: 95
Study 8507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between 0.05% NaF rinse and 0.4% SnF2 gel
Number of subjects: 95
Study 3819572 — intervention group
Group type: EXPERIMENTAL
Intervention: C plus tamoxifen citrate (CT)
Number of subjects: 311
Study 3819572 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus bacillus Calmette‐Guerin (CTBCG)
Number of subjects: 311
Study 3819572 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and 5‐fluorouracil (C)
Number of subjects: 311
Study 29980547 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted physiotherapy
Number of subjects: 48
Study 29980547 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 48
Study 27263997 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 183
Study 27263997 — intervention group
Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 183